U.S. Professional Services Stock News

Acadia Pharmaceuticals has now made DAYBUE STIX, a dye- and preservative-free powder formulation of trofinetide for oral solution, broadly available in the US for treating Rett syndrome in adults and children aged two and older, following its FDA approval in December 2025 and confirmation of bioequivalence to the original DAYBUE oral solution. The launch not only offers caregivers greater flexibility in dose volume and taste, but also comes as Rett experts increasingly view trofinetide as...

If you are wondering whether Copa Holdings at around US$120.90 still offers value or if the easier gains have already been realized, this breakdown can help you frame what the current share price might be implying. The stock returned 8.4% over the last week, 9.5% over the last month, is roughly flat year to date with a 0.8% decline, and sits on a 42.6% return over the last year. This provides useful context before comparing price to fundamentals. Recent coverage has focused on Copa Holdings...

Wondering if Labcorp Holdings at around US$268.87 is still good value or starting to look fully priced, especially after a strong run? This article breaks that question down in plain terms. The stock has recently posted a 6.8% return year to date and 20.2% over the last year, with shorter term moves of 1.9% over 30 days and a slight 0.1% decline over 7 days that may have caught your attention. Recent news coverage has focused on Labcorp's position within the broader healthcare sector,...

Louisiana-Pacific (LPX) shares recently closed at $75.23. The total return over the past 3 months showed an 18.2% decline, and the year-to-date return was 8% lower for investors tracking performance. See our latest analysis for Louisiana-Pacific. Recent share price action has been choppy, with a 7.6% 7 day share price return sitting against a 90 day share price return decline of 18.2% and a weaker 1 year total shareholder return of 11.1%. If Louisiana-Pacific has you reassessing where to find...

Exponent, Inc. has announced a series of leadership changes, including appointing long-time executive Eric Anderson as Chief Financial Officer and promoting Dr. John D. Pye to President, alongside board transitions such as the planned retirement of Dr. Paul R. Johnston and Karen Richardson becoming Chairman. These moves signal a significant internal succession process that elevates leaders with decades of institutional experience in Exponent’s technical, financial, and governance roles,...

Mizuho recently reiterated its positive “Outperform” rating on Arthur J. Gallagher, while institutional investors such as Factory Mutual Insurance Co. reportedly increased their holdings, and the company expanded its Australian footprint by acquiring Brisbane-based International Insurance Brokers Pty Ltd. Together, the analyst endorsement, institutional support, and Australian acquisition highlight how external confidence and geographic expansion could influence Arthur J. Gallagher’s...

CoreCivic Stock Moves After Recent Trading Performance CoreCivic (CXW) has drawn fresh attention after a recent move that leaves the stock at $19.95, with a roughly 10% gain over the past month and a small decline over the past year. See our latest analysis for CoreCivic. That recent 9.6% 1 month share price return sits alongside a 4.9% year to date share price return and a 3 year total shareholder return of about 120%, suggesting momentum has been built over time despite a weaker 1 year...

Johnson & Johnson (JNJ) has opened Q1 2026 with investors focused on how its recent run of earnings ties back to underlying profitability, after reporting Q4 2025 revenue of US$24.6 billion and basic EPS of US$2.10 alongside trailing twelve month EPS of US$11.13 and revenue of US$94.2 billion. Over the last few quarters the company has seen revenue range from US$21.9 billion in Q1 2025 to US$24.6 billion in Q4 2025, while quarterly basic EPS has moved between US$1.41 in Q4 2024 and US$4.57 in...

Cardinal Health released its 2026 Advanced Therapies Report, focusing on how advanced treatments are shifting toward community-based care. The report outlines how providers are rethinking care delivery models to widen patient access outside traditional hospital settings. Findings add new detail to Cardinal Health's role in advanced therapies beyond its previously covered radiopharmaceutical expansions. For investors watching Cardinal Health (NYSE:CAH), the new report lands at a time when...

Ligand Pharmaceuticals recently reported that its partner Travere Therapeutics received full FDA approval for FILSPARI (sparsentan) to reduce proteinuria in adult and pediatric focal segmental glomerulosclerosis (FSGS) patients, the first and only approved treatment for this rare kidney disorder. This approval secures a 9% royalty on worldwide FILSPARI sales for Ligand, potentially strengthening its high-margin royalty portfolio in a specialized nephrology market. Next, we’ll examine how...

Devon Energy (NYSE:DVN) has announced a proposed all stock merger with Coterra Energy, outlining plans for a combined business structure. The company has released unaudited pro forma combined financial statements to illustrate the expected scale and corporate setup of the merged entity. Devon has also filed a shelf registration to allow for potential issuance of various securities in connection with future financing needs. Shares of Devon Energy trade around $45.25, with the stock up 19.5%...

Replimune Group, Inc. recently received a complete response letter from the FDA rejecting its Biologics License Application for RP1 plus nivolumab in advanced melanoma, despite earlier breakthrough therapy designation and priority review based on the IGNYTE trial data set. The company is publicly challenging what it calls inconsistent FDA processes and shifting review teams, highlighting broader tensions around accelerated approvals for oncology drugs. Next, we’ll examine how the FDA’s...

SEI Investments (SEIC) has drawn fresh attention after recent trading left the stock with mixed short term returns, including a small move over the past week and a flat month, while the 1 year total return remains positive. See our latest analysis for SEI Investments. The recent 6.2% 7 day share price return contrasts with weaker 3 month and year to date share price returns. However, multi year total shareholder returns remain solid, which suggests momentum has cooled even as long term...

Earnings slide puts Lindsay (LNN) under closer investor scrutiny Lindsay (LNN) has moved into focus after reporting a year over year decline in both sales and net income for its second quarter and first half of fiscal 2026. The company posted second quarter sales of US$157.72 million and net income of US$12.05 million, compared with US$187.06 million and US$26.58 million a year earlier. This has prompted investors to reassess recent share performance. See our latest analysis for...

DiDi Global’s autonomous driving unit recently unveiled a next‑generation Robotaxi co-developed with GAC Aion, featuring upgraded L4-level self-driving capabilities, an enhanced smart cockpit, and the start of on-road testing. CEO Zhang Bo’s emphasis on a hybrid mobility network that blends human-driven and autonomous vehicles underlines DiDi’s pragmatic approach to deploying AI in complex real-world traffic conditions. We will now examine how DiDi’s focus on a hybrid human-autonomous...

Earlier this month, Truist Securities initiated coverage on BKV Corporation, highlighting its low-risk, cash-generating natural gas operations alongside emerging power and carbon capture businesses. The broker’s focus on BKV’s integrated model, spanning upstream production, midstream, power generation and carbon capture, underlines how the company is positioned at the intersection of conventional gas and lower-carbon energy solutions. We’ll now explore how Truist’s emphasis on BKV’s...

Septerna (SEPN) has begun dosing the first participants in its Phase 1 trial of SEP-479, an oral PTH1R agonist for hypoparathyroidism, marking a key milestone that now puts early safety data in focus. See our latest analysis for Septerna. The Phase 1 dosing update comes as Septerna’s share price sits at $24.13, with a 1-day share price return of 3.38% contrasting with a 90-day share price return of a 9.73% decline and a 1-year total shareholder return of 283.62%. This suggests earlier...

Clinical collaboration puts fresh focus on Incyte stock Incyte (INCY) is back on investor radars after Adagene announced a clinical collaboration, pairing muzastotug with Incyte’s bispecific antibody INCA33890 in microsatellite stable colorectal cancer. The planned Phase 1 study, expected to start in 2026, will be sponsored and conducted by Incyte. It will initially assess safety and tolerability before moving into an efficacy expansion cohort. See our latest analysis for Incyte. The...

Globant (GLOB) has been named an Autodesk Tandem Digital Twin Solution Provider, expanding a 15 year collaboration to support digital twin deployments across airports, smart buildings, manufacturing facilities and logistics environments worldwide. See our latest analysis for Globant. The recent client wins in digital twins and AI based compliance come against a backdrop of a 31.9% decline in the 90 day share price return and a 57.3% fall in the 1 year total shareholder return, suggesting...

Tesla received regulatory approval for its Full Self-Driving supervised technology in the Netherlands after extensive testing. Dutch authorities have started the process for EU wide approval by formally notifying the European Commission. This is the first step that could allow Tesla's supervised autonomous driving system to be legally offered across the European Union. Tesla (NasdaqGS:TSLA) is drawing fresh attention as regulators in the Netherlands back its Full Self-Driving supervised...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Costamare...

Before getting into the numbers, it helps to ask a simple question: at around US$31.65 per share, are you paying a fair price for Kinder Morgan or leaving value on the table? Recent returns have been mixed, with the share price down around 5.0% over the last week and 5.2% over the last month, while still showing a 14.2% gain year to date and 21.3% over the past year. Short-term moves like these often sit against a longer backdrop. In Kinder Morgan's case, the 3 year return is 109.7% and the 5...

Take-Two Interactive Software (NasdaqGS:TTWO) is preparing a new iteration of GTA Online alongside the future launch of Grand Theft Auto VI. The refreshed GTA Online is expected to continue using in-game purchases that have supported recurring, high-margin revenue for the company over the past decade. Investors are watching how this updated online platform could influence the mix and stability of Take-Two's digital revenue profile. For anyone following NasdaqGS:TTWO, the focus now is less...

Match Group stock snapshot after recent gains Match Group (MTCH) has drawn fresh attention after a recent stretch of gains, with the stock up about 9.1% over the past month and 5% over the past 3 months. See our latest analysis for Match Group. The recent 9.1% 30 day share price return and 5.8% year to date share price return sit against a mixed longer record, with an 18.3% 1 year total shareholder return but weaker 3 and 5 year total shareholder returns. This suggests momentum has picked up...